Diagnostics for SARS-CoV-2 detection: A comprehensive review of the FDA-EUA COVID-19 testing landscape

Neeraja Ravi, Dana L Cortade, Elaine Ng, Shan X Wang, Neeraja Ravi, Dana L Cortade, Elaine Ng, Shan X Wang

Abstract

The rapidly spreading outbreak of COVID-19 disease is caused by the SARS-CoV-2 virus, first reported in December 2019 in Wuhan, China. As of June 17, 2020, this virus has infected over 8.2 million people but ranges in symptom severity, making it difficult to assess its overall infection rate. There is a need for rapid and accurate diagnostics to better monitor and prevent the spread of COVID-19. In this review, we present and evaluate two main types of diagnostics with FDA-EUA status for COVID-19: nucleic acid testing for detection of SARS-CoV-2 RNA, and serological assays for detection of SARS-CoV-2 specific IgG and IgM patient antibodies, along with the necessary sample preparation for accurate diagnoses. In particular, we cover and compare tests such as the CDC 2019-nCoV RT-PCR Diagnostic Panel, Cellex's qSARS-CoV-2 IgG/IgM Rapid Test, and point-of-care tests such as Abbott's ID NOW COVID-19 Test. Antibody testing is especially important in understanding the prevalence of the virus in the community and to identify those who have gained immunity. We conclude by highlighting the future of COVID-19 diagnostics, which include the need for quantitative testing and the development of emerging biosensors as point-of-care tests.

Keywords: COVID-19; Diagnostic testing; FDA-EUA; Immunoassay; Point-of-care; RT-PCR; SARS-CoV-2.

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Copyright © 2020 Elsevier B.V. All rights reserved.

Figures

Fig. 1
Fig. 1
SARS-CoV-2 Virus structure, with five main proteins. Details of protein function can be found in Table 1.
Fig. 2
Fig. 2
Time course of approximate concentrations of viral RNA, antigen, and antibodies after symptom onset for a hypothetical patient with SARS-CoV-2. Diagnostic testing consists of both RT-PCR and antigen testing. While exact numbers on the duration of the antibody response are still being determined at this writing, in general, RT-PCR and antigen testing are effective to diagnose active infection when viral RNA or antigen is present. Serological assays are effective after about 5 days to detect IgM, with IgG rising afterwards (Guo et al., 2020).

References

    1. Abbott Diagnostics Scarborough, Inc. ID NOW COVID-19. 2020.
    1. Abbott, Inc SARS-COV-IMMUNOASSAYS. 2020.
    1. Abbott Laboratories . 2020. ALINITY m SARS-COV-2 ASSAY.
    1. Amanat F., Nguyen T., Chromikova V., Strohmeier S., Stadlbauer D., Javier A., Jiang K., Asthagiri-Arunkumar G., Polanco J., Bermudez-Gonzalez M., Caplivski D., Cheng A., Kedzierska K., Vapalahti O., Hepojoki J., Simon V., Krammer F. A serological assay to detect SARS-CoV-2 seroconversion in humans. medRxiv. 2020;2020 doi: 10.1101/2020.03.17.20037713. 03.17.20037713.
    1. American Society of Microbiology . 2020. ASM Expresses Concern about Coronavirus Test Reagent Shortages.
    1. Andres-Terre M., McGuire H.M., Pouliot Y., Bongen E., Sweeney T.E., Tato C.M., Khatri P. Integrated, multi-cohort analysis identifies conserved transcriptional signatures across multiple respiratory Viruses. Immunity. 2015;43(6):1199–1211. doi: 10.1016/j.immuni.2015.11.003.
    1. Autobio Diagnostics Co, Ltd . 2020. Anti-SARS-CoV-2 Rapid Test.
    1. Avellino Lab USA, Inc AvellioCoV2 test. 2020.
    1. Bao L., Deng W., Gao H., Xiao C., Liu J., Xue J., Lv Q., Liu J., Yu P., Xu Y., Qi F., Qu Y., Li F., Xiang Z., Yu H., Gong S., Liu M., Wang G., Wang S., Qin C. Reinfection could not occur in SARS-CoV-2 infected rhesus macaques [Preprint] Microbiology. 2020 doi: 10.1101/2020.03.13.990226.
    1. Becton Dickinson, Company . 2020. BioGX SARS-CoV-2 Reagents for BD MAX System.
    1. Bendavid E., Mulaney B., Sood N., Shah S., Ling E., Bromley-Dulfano R., Lai C., Weissberg Z., Saavedra R., Tedrow J., Tversky D., Bogan A., Kupiec T., Eichner D., Gupta R., Ioannidis J., Bhattacharya J. COVID-19 antibody seroprevalence in santa clary county, California. medRxiv. 2020;2020 doi: 10.1101/2020.04.14.20062463. 04.14.20062463.
    1. BGI Genomics Co Ltd Real-time fluorescent RT-PCR kit for detecting SARS-2019-nCoV. 2020.
    1. Bhalla N., Jolly P., Formisano N., Estrela P. Introduction to biosensors. Essays Biochem. 2016;60(1):1–8.
    1. Bio-Rad Laboratories . 2020. Platelia SARS-CoV-2 Total Ab Assay #72710.
    1. BioFire Defense L. 2020. BioFire ® COVID-19 Test.
    1. Blanco-Melo D., Nilsson-Payant B.E., Liu W.-C., Møller R., Panis M., Sachs D., Albrecht R.A., tenOever B.R. SARS-CoV-2 launches a unique transcriptional signature from in vitro, ex vivo, and in vivo systems [Preprint] Microbiology. 2020 doi: 10.1101/2020.03.24.004655.
    1. Bradley T., Ferrari G., Haynes B.F., Margolis D.M., Browne E.P. Single-cell analysis of quiescent HIV infection reveals host transcriptional profiles that regulate proviral latency. Cell Rep. 2018;25(1):107–117. doi: 10.1016/j.celrep.2018.09.020. e3.
    1. British Society for Immunology . 2020. Enzyme-linked Immunosorbent Assay (ELISA)
    1. Brookings Institution . 2020. How the CARES Act Affects COVID-19 Test Pricing.
    1. Casadevall A., Pirofski L. The convalescent sera option for containing COVID-19. J. Clin. Invest. 2020;130(4):1545–1548. doi: 10.1172/JCI138003.
    1. CDC . 2020. CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel.
    1. CDC . 2020. COVID-19 Pandemic Planning Scenarios.
    1. CDC . 2020. FAQs on COVID-19 Testing at Laboratories.
    1. CDC . 2020. Frequently Asked Questions about Coronavirus (COVID-19) for Laboratories.
    1. CDC . 2020. Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons for Coronavirus Disease 2019 (COVID-19)
    1. CDC . 2020. Interim Guidelines for COVID-19 Antibody Testing.
    1. CDC . 2020. Overview of Testing for SARS-CoV-2.
    1. CDC . 2020. Situation Summary.
    1. CDC . 2020. Testing for COVID-19.
    1. CDC . 2020. Using Antibody Tests for COVID-19.
    1. Cellex Inc qSARS-CoV-2 IgG/IgM rapid test. 2020.
    1. Cepheid . 2020. Xpert Xpress SARS-CoV-2 Test (POC)
    1. Chembio Diagnostics Systems, Inc . 2020. DPP® COVID-19 IgM/IgG System.
    1. Cheng M.P., Papenburg J., Desjardins M., Kanjilal S., Quach C., Libman M., Dittrich S., Yansouni C. Diagnostic testing for severe acute respiratory syndrome–related coronavirus-2: a narrative review. Ann. Intern. Med. 2020 doi: 10.7326/M20-1301. [Epub ahead of print 13 April 2020]
    1. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol. 2020;5(4):536–544. doi: 10.1038/s41564-020-0695-z.
    1. Cue Health . 2020. The Cue Health Monitoring System.
    1. Cue Health . 2020. Cue Health Awarded $13 Million for Rapid, Portable, Point-of-Care COVID-19 Test by U.S. Department of Health and Human Services Biomedical Advanced Research and Development Authority (“BARDA”)
    1. DiaSorin Molecular L.L.C. 2020. SimplexaTM COVID-19 Direct.
    1. Dutta N., Mazumdar K., Gordy J. The nucleocapsid protein of SARS–CoV-2: a target for vaccine development. J. Virol. 2020;94(13) doi: 10.1128/jvi.00647-20.
    1. Fan B.E., Lim K.G.E., Chong V.C.L., Chan S.S.W., Ong K.H., Kuperan P. COVID-19 and mycoplasma pneumoniae coinfection. Am. J. Hematol. 2020 doi: 10.1002/ajh.25785.
    1. FDA . 2020. Emergency Use Authorizations.
    1. FDA . 2020. MOU 225-14-017.
    1. FDA . 2020. FAQs on Diagnostic Testing for SARS-CoV-2.
    1. Guan W., Ni Z., Hu Y., Liang W., Ou C., He J., Liu L., Shan H., Lei C., Hui D.S.C., Du B., Li L., Zeng G., Yuen K.-Y., Chen R., Tang C., Wang T., Chen P., Xiang J., Zhong N. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 2020 doi: 10.1056/NEJMoa2002032.
    1. Guo L., Ren L., Yang S., Xiao M., Chang D., Yang F., Wang J. Clinical Infectious Diseases; 2020. Profiling early humoral response to diagnose novel coronavirus disease (COVID-19)
    1. Hologic, Inc . 2020. Panther Fusion SARS-CoV-2 Assay.
    1. Indwiani A., Ysrafil Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2020;14(4) doi: 10.1016/j.dsx.2020.04.020.
    1. Informa . 2020. COVID-19 Puts the World Health Organization's Emergency Use Listing (EUL) to Work.”.
    1. Ipsum Diagnostics LLC . 2020. COV-19 IDx Assay.
    1. Johns Hopkins Center for Health Security . 2020. Comparison of National RT-PCR Primers, Probes, and Protocols for SARS-Cov-2 Diagnostics.
    1. Johns Hopkins University . 2020. Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU)
    1. Koczula K.M., Gallotta A. Lateral flow assays. Essays Biochem. 2016;60(1):111–120. doi: 10.1042/EBC20150012.
    1. LabCorp . LABORATORY CORPORATION OF AMERICA; 2020. COVID-19 RT-PCR TEST.
    1. Lai C.C., Shih T.P., Ko W.C., Tang H.J., Hsueh P.R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int. J. Antimicrob. Agents. 2020;55
    1. Layqah L., Eissa S. An electrochemical immunosensor for the corona virus associated with the Middle East respiratory syndrome using an array of gold nanoparticle-modified carbon electrodes. Microchimica Acta. 2019;186(4)
    1. Legutki J.B., Johnston S.A. Immunosignatures can predict vaccine efficacy. Proc. Natl. Acad. Sci. Unit. States Am. 2013;110(46):18614–18619. doi: 10.1073/pnas.1309390110.
    1. Li Y., Xia L. Coronavirus disease 2019 (COVID-19): role of chest CT in diagnosis and management. Am. J. Roentgenol. 2020;1–7 doi: 10.2214/AJR.20.22954.
    1. Liang T. The First Affiliated Hospital, Zhejiang University School of Medicine; Hangzhou, China: 2020. Handbook of COVID-19 Prevention and Treatment.
    1. Lin C., Xiang J., Yan M., Li H., Huang S., Shen C. Comparison of throat swabs and sputum specimens for viral nucleic acid detection in 52 cases of novel coronavirus (SARS-Cov-2)-infected pneumonia (COVID-19) Clin. Chem. Lab. Med. 2020;58(7):1089–1094. doi: 10.1515/cclm-2020-0187.
    1. Long Q., Tang X., Shi Q., Li Q., Deng H., Yuan J. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat. Med. 2020 doi: 10.1038/s41591-020-0965-6.
    1. Lu R., Zhao X., Li J., Niu P., Yang B., Wu H., Wang W., Song H., Huang B., Zhu N., Bi Y., Ma X., Zhan F., Wang L., Hu T., Zhou H., Hu Z., Zhou W., Zhao L., Tan W. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565–574. doi: 10.1016/S0140-6736(20)30251-8.
    1. Lucigen . 2020. Loop-Mediated Isothermal Amplification (LAMP) Primer Design and Assay Optimization.
    1. Luminex Molecular Diagnostics Inc . 2020. NxTAG ® CoV Extended Panel Assay Package Insert.
    1. Mesa Biotech Inc . 2020. Accula SARS-CoV-2 Test.
    1. MonobindInc . 2020. CLIA Advantages.
    1. Nelson P., Rath B., Fragkou P., Antalis E., Tsiodras S., Skevaki C. Current and future point-of-care tests for emerging and new respiratory Viruses and future perspectives. Front. Cell. and Infection Microbiol. 2020;10
    1. NeuMoDx Molecular I. 2020. NeuMoDxTM SARS-CoV-2 Assay INTENDED USE.
    1. New York Times . 2020. Most Coronavirus Tests Cost about $100. Why Did One Cost $2,315?
    1. npr . 2020. Insurers May Only Pay for Coronavirus Tests when They're 'Medically Necessary.
    1. Okba N.M.A., Muller M.A., Li W., Wang C., GeurtsvanKessel C.H., Corman V.M., Lamers M.M., Sikkema R.S., de Bruin E., Chandler F.D., Yazdanpanah Y., Le Hingrat Q., Descamps D., Houhou-Fidouh N., Reusken C.B.E.M., Bosch B.-J., Drosten C., Koopmans M.P.G., Haagmans B.L. Infectious Diseases (Except HIV/AIDS) 2020. SARS-CoV-2 specific antibody responses in COVID-19 patients [Preprint]
    1. OraSure Technologies Development. 2020.
    1. Ortho-Clinical Diagnostics, Inc . 2020. Instructions for Use: VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total 619 9922 Reagent Pack.
    1. Payne D.C., Iblan I., Rha B., Alqasrawi S., Haddadin A., Al Nsour M., Alsanouri T., Ali S.S., Harcourt J., Miao C., Tamin A., Gerber S.I., Haynes L.M., Al Abdallat M.M. Persistence of antibodies against Middle East respiratory syndrome coronavirus. Emerg. Infect. Dis. 2016;22(10):1824–1826. doi: 10.3201/eid2210.160706.
    1. PerkinElmer I. 2020. PerkinElmer® New Coronavirus Nucleic Acid Detection Kit V 2.0.
    1. Plotkin S.A. Correlates of protection induced by vaccination. Clin. Vaccine Immunol. 2010;17(7):1055–1065. doi: 10.1128/CVI.00131-10.
    1. Premkumar L., Segovia-Chumbez B., Jadi R., Martinez D., Raut R., Markmann A., Cornaby C., Bartelt L., Weiss S., Park Y., Edwards C., Weimer E., Scherer E., Rouphael N., Edupuganti S., Weiskopf D., Tse L., Hou Y., Margolis D., Sette A., Collins M., Schmitz J., Baric R., de Silva A. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci. Immunol. 2020;5(48)
    1. Primerdesign Ltd . 2020. Genesig ® Real-Time PCR Assay.
    1. QIAGEN GmbH . 2020. QIAstat-Dx ® Respiratory SARS-CoV-2 Panel Instructions for Use (Handbook)
    1. Quest Diagnostics Infectious Disease I. 2020. Quest SARS-CoV-2 rRT-PCR.
    1. Quidel Corporation . 2020. Lyra® SARS-CoV-2 Assay.
    1. Quidel Corporation . 2020. Sofia SARS Antigen FIA.
    1. Roche Diagnostics . 2020. Elecsys® Anti-SARS-cov-2.
    1. Roche Molecular Systems . 2020. I. Cobas ® SARS-CoV-2 Qualitative Assay.
    1. ScienceDaily . 2020. Super-Potent Human Antibodies Protect against COVID-19 in Animal Tests: Scientists Isolate Powerful Coronavirus-Neutralizing Antibodies from COVID-19 Patients and Successfully Test in Animals. 2020.
    1. Seo G., Lee G., Kim M., Baek S., Choi M., Ku K., Lee C., Jun S., Park D., Kim H., Kim S., Lee J., Kim B., Park E., Kim S. Rapid detection of COVID-19 causative virus (SARS-CoV-2) in human nasopharyngeal swab specimens using field-effect transistor-based biosensor. ACS Nano. 2020;14(4):5135–5142.
    1. Sethuraman N., Jeremiah S., Ryo A. Interpreting diagnostic tests for SARS-CoV-2. J. Am. Med. Assoc. 2020;323(22):2249.
    1. Siemens Medical Solutions . 2020. Inc. SARS-CoV-2 Total Assay.
    1. Sigma-Aldrich . CLIA/CLEIA) Development; 2020. Complete Solutions for IVD Chemiluminescent Immunoassay.
    1. Sonora Quest Laboratories . 2020. Coronavirus: what You Need to KNOW.
    1. Steinbrink J.M., Hua K., Myers R., Johnson M.D., Seidelman J., Tsalik E.L., Tsalik E.L., Alexander B.D., McClain M.T. 2885. A host transcriptional signature for accurate diagnosis of candidemia in the hospital setting. Open Forum Infectious Dis. 2019;6(Suppl. ment_2) doi: 10.1093/ofid/ofz359.163. S76–S76.
    1. Sweeney T.E., Braviak L., Tato C.M., Khatri P. Genome-wide expression for diagnosis of pulmonary tuberculosis: a multicohort analysis. The Lancet. Respir. Med. 2016;4(3):213–224. doi: 10.1016/S2213-2600(16)00048-5.
    1. The Conversation US Inc . 2020. There Are Many COVID-19 Tests in the US – How Are They Being Regulated?
    1. Thermo Fisher Scientific . 2020. TaqPath TM COVID-19 Combo Kit.
    1. Thermo Fisher Scientific . 2020. The Basics: RNA Isolation.
    1. Tyrrell D.A.J., Myint S.H. Coronaviruses. In: Baron S., editor. Medical Microbiology. fourth ed. University of Texas Medical Branch at Galveston; 1996.
    1. Vogel G. New blood tests for antibodies could show true scale of coronavirus pandemic. Science. 2020;80– doi: 10.1126/science.abb8028.
    1. Wadsworth Center, N.Y.S. D.of P.H.CDC . 2020. New York SARS-CoV-2 Real-Time Reverse Transcriptase (RT)-PCR Diagnostic Panel.
    1. Wang P. Combination of serological total antibody and RT-PCR test for detection of SARS-COV-2 infections. J. Virol Methods. 2020;283 doi: 10.1016/j.jviromet.2020.113919.
    1. Wang Y., Kang H., Liu X., Tong Z. Combination of RT‐qPCR testing and clinical features for diagnosis of COVID‐19 facilitates management of SARS‐CoV‐2 outbreak. J. Med. Virol. jmv. 2020;25721 doi: 10.1002/jmv.25721.
    1. WHO . 2020. Advice on the Use of Point-Of-Care Immunodiagnostic Tests for COVID-19.
    1. WHO . 2020. WHO Director-General's Remarks at the Media Briefing on 2019-nCoV on 11 February 2020.
    1. WHO . 2020. WHO Director-General's Remarks at the Media Briefing on 2019-nCoV on 11 March 2020.
    1. WHO . 2020. Laboratory Testing for 2019 Novel Coronavirus (2019-nCoV) in Suspected Human Cases.
    1. Wu L.-P., Wang N.-C., Chang Y.-H., Tian X.-Y., Na D.-Y., Zhang L.-Y., Zheng L., Lan T., Wang L.-F., Liang G.-D. Duration of antibody responses after severe acute respiratory syndrome. Emerg. Infect. Dis. 2007;13(10):1562–1564. doi: 10.3201/eid1310.070576.
    1. Wu K., Klein T., Krishna V., Su D., Perez A., Wang J. Portable GMR handheld platform for the detection of influenza A virus. ACS Sens. 2017;2(11):1594–1601.
    1. Xing Q., Li G., Xing Y., Chen T., Li W., Ni W., Deng K., Gao R., Chen C., Gao Y., Li Q., Yu G., Tong J., Li W., Hao G., Sun Y., Zhang A., Wu Q., Li Z., Pan S. Precautions are needed for COVID-19 patients with coinfection of common respiratory pathogens. SSRN Electron. J. 2020 doi: 10.2139/ssrn.3550013.
    1. Yang Y., Yang M., Shen C., Wang F., Yuan J., Li J., Zhang M., Wang Z., Xing L., Wei J., Peng L., Wong G., Zheng H., Liao M., Feng K., Li J., Yang Q., Zhao J., Zhang Z., Liu Y. 2020. Evaluating the Accuracy of Different Respiratory Specimens in the Laboratory Diagnosis and Monitoring the Viral Shedding of 2019-nCoV Infections [Preprint]. Infectious Diseases (Except HIV/AIDS)
    1. Zhai Y., Franco L.M., Atmar R.L., Quarles J.M., Arden N., Bucasas K.L., Wells J.M., Niño D., Wang X., Zapata G.E., Shaw C.A., Belmont J.W., Couch R.B. Host transcriptional response to influenza and other acute respiratory viral infections – a prospective cohort study. PLoS Pathog. 2015;11(6) 8. 9, 386–389.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj